Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 1/20 | 0.35 |
| ▸ | GLS | O94925 | 4/20 | 0.34 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 5/20 | 0.32 |
| ▸ | JAK1 | P23458 | 5/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29760088 | 1.00 | POLQ (0.35) | POLQGLSTP53MAPTIRAK4 | |
| SCHEMBL24578989 | 0.89 | POLQ (0.37) | POLQCDK9NTRK1KIT | |
| SCHEMBL29759606 | 0.89 | POLQ (0.37) | POLQCDK9NTRK1KIT | |
| SCHEMBL29759976 | 0.87 | POLQ (0.37) | POLQCDK9NTRK1KIT | |
| SCHEMBL27185213 | 0.87 | POLQ (0.37) | POLQCDK9NTRK1KIT | |
| SCHEMBL29759651 | 0.85 | IDO1 (0.36) | GLSTP53MAPTIRAK4GAA | |
| SCHEMBL27185073 | 0.85 | IDO1 (0.36) | GLSTP53MAPTIRAK4GAA | |
| SCHEMBL29760080 | 0.84 | POLQ (0.39) | POLQCDK9NTRK1KIT | |
| SCHEMBL27185204 | 0.84 | POLQ (0.39) | POLQCDK9NTRK1KIT | |
| SCHEMBL29760155 | 0.83 | POLQ (0.37) | POLQNTRK1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109917-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2024-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109917-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | PDGFRA, PDGFRB, ABL1 | POLQ 2881/4885GLS 124/4885TP53 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.